Propanc Biopharma, Inc.

Latest News

May 11, 2020

Propanc Biopharma Provides Shareholder Update

MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring…

View All Press Releases

Apr 16, 2020

How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are Increasingly Vulnerable to the COVID-19 Global Pandemic

Apr 14, 2020

Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office

Mar 31, 2020

Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor
Latest Publication Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting View All Publications
Antitumour efficacy of chymotrypsinogen and trypsinogen
In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation
A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer